Emmaus Life Sciences Inc.
NASDAQ:EMMA (9/10/2019, 7:00:00 PM)
After market: 2.73 -0.04 (-1.44%)2.77
-1.72 (-38.31%)
Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company. It is engaged in the discovery, development, marketing and sale of treatments and therapies, for rare and orphan disease categories. Emmaus Life Sciences Inc., formerly known MYnd Analytics Inc., is based in Torrance, United States.
Emmaus Life Sciences Inc.
21250 Hawthorne Boulevard Suite 800
Torrance CA 90503
P: 310-214-0065
CEO: George C. Carpenter
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
/PRNewswire-HISPANIC PR WIRE/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), líder en el tratamiento de la anemia falciforme, también denominada enfermedad de...
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received marketing...
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Here you can normally see the latest stock twits on EMMA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: